01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
01:39 , Jun 29, 2019 |  BioCentury  |  Finance

Specialists and strong fundamentals must carry the sector in 3Q19

Heading into the third quarter, specialist biotech investors are in the driver’s seat, and their stances on whether to trim or spend in the down market are split. After recovering at the start of the...
22:56 , Jun 28, 2019 |  BC Extra  |  Company News

CHMP knocks Evenity for osteoporosis, backs Giapreza for hypotension

EMA's CHMP issued a basket of opinions Friday, including a negative opinion for Amgen's osteoporosis drug Evenity, and a recommendation for La Jolla's hypotension therapy Giapreza. The agency recommended against approval of Evenity romosozumab-aqqg from...
23:45 , Jun 19, 2019 |  BC Extra  |  Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

G1 rises on trilaciclib OS efficacy in Phase II for TNBC  G1 Therapeutics Inc. (NASDAQ:GTHX) has gained 33% to $26.27 since reporting preliminary data Tuesday from a Phase II trial showing a statistically significant improvement...
23:12 , Jun 19, 2019 |  BC Extra  |  Company News

Gilead adds targeted degradation via Nurix deal in quest to strengthen growth areas

Just three months after Daniel O'Day took the helm, Gilead has pulled the trigger on adding targeted protein degradation to its modality tool kit in areas it has tagged as growth drivers. Wednesday’s announcement of...
23:50 , Jun 14, 2019 |  BC Extra  |  Clinical News

June 14 Clinical Quick Takes: Chi-Med, BeiGene, UCB, Global Blood and more

Chi-Med’s surufatinib meets in Phase III for extra-pancreatic neuroendocrine tumors  Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said it is planning a pre-NDA meeting with China’s National Medical Products Administration (NMPA) after surufatinib (formerly sulfatinib) met...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
00:36 , Jun 8, 2019 |  BioCentury  |  Product Development

ASCO 2019 sessions provide guidance on expanding patient pools for clinical trials

Two sessions at this year's American Society of Clinical Oncology meeting gave drug developers a glimpse of how to match more patients to clinical trials by broadening eligibility criteria and encouraging trial enrollment in community...
18:51 , May 31, 2019 |  BC Extra  |  Financial News

May 31 Financial Quick Takes: Mabpharm prices Hong Kong IPO; plus follow-ons from Amicus, Myovant and more

Mabpharm down in first day of Hong Kong trading  Mabpharm Ltd. (HKSE:2181) lost HK$0.29 to HK$1.21 in its first day of trading Friday after raising HK$1.2 billion ($149.7 million) in a Hong Kong IPO Thursday...
14:20 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

The OXPHOS complex I inhibitor IACS-010759 for mantle cell and B cell lymphoma

DISEASE CATEGORY: Cancer INDICATION: Mantle cell lymphoma (MCL); B cell lymphoma Patient sample, cell culture and mouse studies identified an OXPHOS complex I inhibitor that could help treat MCL and B cell lymphoma that are...